CN  |  EN

News & Events
/
/
Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection Approved by NMPA

Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection Approved by NMPA

  • Categories:News & Events
  • Author:
  • Origin:
  • Time of issue:2022-07-07 16:08
  • Views:

(Summary description)

Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection Approved by NMPA

(Summary description)

  • Categories:News & Events
  • Author:
  • Origin:
  • Time of issue:2022-07-07 16:08
  • Views:
Information

Congratulations to Akesobio Pharmaceuticals for Cadonilimab (PD-1/CTLA-4) injection, the first market approved novel bispecific immune-oncology product by NMPA. Cadonilimab fully exploits the synergistic anti-tumor effect of two immune checkpoint inhibitors, PD-1 & CTLA-4, with significantly fewer side effects than the combination of two monoclonal antibodies with the relevant targets. At recent years, UP-Pharma has proudly provided bioanalytical supports to further expedite Akesobio ongoing clinical development studies in tumor treatment. The effective and fruitful collaboration helped the acceleration of drug development programs and bringing better medicine to patients.

Scan the QR code to read on your phone

Contact Us

Beijing Address:Tower B, No.33 Science Park Road, Changping District, Beijing, P. R. China 102206

Shanghai Address:Building 30, Lane 908, Ziping Road, Pudong New Area, Shanghai, P. R. China 201318

Tianjin Address:Building B03, Venture Headquarters, Fuyuan Road North, Wuqing Development Zone, Tianjin, P. R. China  301700

Guangxi Address:Building 3, Yunlang Science Park, Fangcheng District, Fangchenggang City, Guangxi,P. R. China 838000 

Business Email:BD@up-pharma.com

Recruitment Email:hr@up-pharma.com

WeChat

WeChat

Copyright © 2022 United-Power Pharma Tech Co., Ltd (UPP) All Rights Reserved   京ICP备15042399